Fidelity Management & Research Co recently announced the acquisition of new stake in Janux Therapeutics Inc. (NASDAQ:JANX). The institutional investor has increased its shareholding in the Healthcare company by 7.24% to 6.25 million shares with purchase of 0.42 million shares. This fresh investment now brings its stake to 14.99% valued currently at $85.21 million. In addition, BlackRock Fund Advisors raised its holdings by 35910.0 to 1.13 million shares. And The Vanguard Group, Inc. has lifted its position by 17.39% or 0.11 million shares – to 0.75 million shares.
With over 0.99 million Janux Therapeutics Inc. (JANX) shares trading Tuesday and a closing price of $15.07 on the day, the dollar volume was approximately $14.96 million. The shares have shown a positive half year performance of 3.93% and its price on 01/10/23 gained nearly 5.75%. Currently, there are 41.53M common shares owned by the public and among those 37.08M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for JANX have a consensus price objective of $29.67. The analysts have set the share’s price value over the next 12 months at a high of $35.00 and a low of $25.00. The average price target is 49.21% above its recent price level and an upside to the estimated low will see the stock gain 39.72% over that period. But an upside of 56.94% will see the stock hit the forecast high price target while median target price for the stock is $29.00.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Janux Therapeutics Inc. are Fidelity Select Port. – Biotechno, Fidelity Series Small Cap Opportu, and Janus Henderson Global Life Scien. Fidelity Select Port. – Biotechno owns 0.72 million shares of the company’s stock, all valued at over $9.8 million. The company sold 24557.0 shares recently to bring their total holdings to about 1.72% of the shares outstanding. Janus Henderson Global Life Scien sold 64042.0 shares to bring its total holdings to over 0.56 million shares at a value of $7.58 million. Janus Henderson Global Life Scien now owns shares totaling to 1.33% of the shares outstanding.
Shares of Janux Therapeutics Inc. (NASDAQ: JANX) opened at $14.17, down -$0.08 from a prior closing price of $14.25. However, the script later moved the day high at 15.25, up 5.75%. The company’s stock has a 5-day price change of 7.49% and 14.86% over the past three months. JANX shares are trading 14.43% year to date (YTD), with the 12-month market performance down to -18.54% lower. It has a 12-month low price of $9.39 and touched a high of $19.68 over the same period. JANX has an average intraday trading volume of 89.55K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 16.59%, 3.39%, and 13.06% respectively.
Institutional ownership of Janux Therapeutics Inc. (NASDAQ: JANX) shares accounts for 99.10% of the company’s 41.53M shares outstanding. Mutual fund holders own 39.78%, while other institutional holders and individual stakeholders account for 7.02% and 22.47% respectively.
It has a market capitalization of $655.85M. The earnings-per-share (ttm) stands at -$1.46. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.02% over the week and 8.73% over the month.
Analysts forecast that Janux Therapeutics Inc. (JANX) will achieve an EPS of -$0.49 for the current quarter, -$0.5 for the next quarter and -$2.46 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.53 while analysts give the company a high EPS estimate of -$0.45. Comparatively, EPS for the current quarter was -$0.26 a year ago. Earnings per share for the fiscal year are expected to decrease by -716.70%, and -31.70% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate Janux Therapeutics Inc. (JANX) as a “Strong Buy” at a consensus score of 1.60. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 0 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”